Literature DB >> 8856159

Vasomotor and permeability effects of bradykinin in the cerebral microcirculation.

M Wahl1, E T Whalley, A Unterberg, L Schilling, A A Parsons, A Baethmann, A R Young.   

Abstract

All components of an intracerebral kallikrein-kinin system have been described. Thus, bradykinin (BK) acting from the parenchymal site as well as from the blood site may influence cerebral microcirculation. BK is a potent dilator of extra- and intraparenchymal cerebral arteries when acting from the perivascular site. The vasomotor effect of BK is mediated by B2 receptors which appear to be located at the abluminal membrane of the endothelial cell. The effect of BK is mediated by NO. prostanoids, free radicals, H2O2 or leukotrienes depending on the animal species and on the location of the artery. Selective opening of the blood-brain barrier for small tracers (Na(+)-fluorescein; MW, 376) has been found in cats during cortical superfusion or intraarterial application of BK. This leakage is mediated by B2 receptors located at the luminal and abluminal membrane of the endothelial cells. Formation of brain edema has been found after ventriculo-cisternal perfusion or interstitial infusion of BK. This can be explained by increase of vascular permeability and cerebral blood flow due to arterial dilation thus enhancing driving forces for the extravasation. An increase of the BK concentration in the interstitial space of the brain up to concentrations which induce extravasation, dilatation and oedema formation has been found under several pathological conditions. Thus, BK may be involved in oedema formation after cold lesion, concussive brain injury, traumatic spinal cord and ischemic brain injury. The mediator role of BK in brain edema is further supported by therapeutic results. Brain swelling due to cold lesion or ischemia could be diminished by treatment with kallikrein-inhibitors. Similarly, dilatation of cerebral arterioles after concussive brain injury was reduced by blockade of B2 receptors. Thus, all criteria favour BK as one mediator of vasogenic oedema.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8856159     DOI: 10.1016/0162-3109(96)00068-9

Source DB:  PubMed          Journal:  Immunopharmacology        ISSN: 0162-3109


  8 in total

Review 1.  Involvement of bradykinin in brain edema development after ischemic stroke.

Authors:  Marina Dobrivojević; Katarina Špiranec; Aleksandra Sinđić
Journal:  Pflugers Arch       Date:  2014-04-23       Impact factor: 3.657

2.  Cereport (RMP-7) increases the permeability of human brain microvascular endothelial cell monolayers.

Authors:  J B Mackic; M Stins; S Jovanovic; K S Kim; R T Bartus; B V Zlokovic
Journal:  Pharm Res       Date:  1999-09       Impact factor: 4.200

3.  LF 16-0687 Ms, a bradykinin B2 receptor antagonist, reduces ischemic brain injury in a murine model of transient focal cerebral ischemia.

Authors:  Li Ding-Zhou; Isabelle Margaill; Bruno Palmier; Didier Pruneau; Michel Plotkine; Catherine Marchand-Verrecchia
Journal:  Br J Pharmacol       Date:  2003-08       Impact factor: 8.739

Review 4.  Bradykinin B2 receptor antagonism: a new direction for acute stroke therapy?

Authors:  Christopher G Sobey
Journal:  Br J Pharmacol       Date:  2003-08       Impact factor: 8.739

5.  Induction of selective blood-tumor barrier permeability and macromolecular transport by a biostable kinin B1 receptor agonist in a glioma rat model.

Authors:  Jérôme Côté; Veronica Bovenzi; Martin Savard; Céléna Dubuc; Audrey Fortier; Witold Neugebauer; Luc Tremblay; Werner Müller-Esterl; Ana-Maria Tsanaclis; Martin Lepage; David Fortin; Fernand Gobeil
Journal:  PLoS One       Date:  2012-05-21       Impact factor: 3.240

6.  The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury.

Authors:  Haleema Shakur; Peter Andrews; Toomas Asser; Laura Balica; Cristian Boeriu; Juan Diego Ciro Quintero; Yashbir Dewan; Patrick Druwé; Olivia Fletcher; Chris Frost; Bennie Hartzenberg; Jorge Mejia Mantilla; Francisco Murillo-Cabezas; Jan Pachl; Ramalingam R Ravi; Indrek Rätsep; Cristina Sampaio; Manmohan Singh; Petr Svoboda; Ian Roberts
Journal:  Trials       Date:  2009-12-03       Impact factor: 2.279

7.  Effect of Bradykinin Postconditioning on Ischemic and Toxic Brain Damage.

Authors:  Mária Lalkovičová; Petra Bonová; Jozef Burda; Viera Danielisová
Journal:  Neurochem Res       Date:  2015-07-28       Impact factor: 3.996

8.  Cognitive and cerebrovascular improvements following kinin B1 receptor blockade in Alzheimer's disease mice.

Authors:  Baptiste Lacoste; Xin-Kang Tong; Karim Lahjouji; Réjean Couture; Edith Hamel
Journal:  J Neuroinflammation       Date:  2013-05-04       Impact factor: 8.322

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.